- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
High-Risk Features Could Guide Treatment Intensification in First-Line EGFR-Mutated NSCLC
July 25th 2025, 6:39pm
International Lung Cancer Congress
Lyudmila A. Bazhenova, MD, discusses considerations for treatment intensification in patients with EGFR-mutated NSCLC.
Dr Nieva on the Rationale for Comparing ALK Inhibitors in ALK+ NSCLC
July 24th 2025, 12:15am
Bridging the Gaps in Lung Cancer
Jorge Nieva, MD, discusses matched-adjusted indirect comparison data evaluating crizotinib vs alectinib, brigatinib, and lorlatinib in ALK-positive NSCLC.
Dr Patel on Toxicities Associated With Immunotherapy-Based Combinations in NSCLC
July 23rd 2025, 11:55pm
Bridging the Gaps in Lung Cancer
Sandip P. Patel, MD, discusses toxicities associated with the use of immunotherapy-based combination regimens in patients with advanced NSCLC.
Dr Shum on Evolving First-Line Treatment Approaches for EGFR-Mutant NSCLC
July 23rd 2025, 1:00am
Bridging the Gaps in Lung Cancer
Elaine Shum, MD, discusses questions that remain regarding the first-line treatment paradigm for patients with EGFR-mutant non–small cell lung cancer.
Dr Donington on the Evolving Use of Perioperative Nivolumab in Resectable NSCLC
July 22nd 2025, 11:00pm
Bridging the Gaps in Lung Cancer
Jessica Donington, MD, MSCR, discusses how updated data with perioperative nivolumab in NSCLC may affect future surgical decision-making.
Casdatifan Plus Cabozantinib Shows Meaningful Clinical Activity in Pretreated ccRCC
July 18th 2025, 9:25pm
Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.
High Levels of CD163+ Tumor-Associated Macrophages Could Improve Outcomes With Nivolumab in Metastatic RCC
July 18th 2025, 9:19pm
High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.
KIM-1 Represents a Potential Biomarker for Outcomes and Response in RCC
July 18th 2025, 7:02pm
KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.
Dr Kotecha on the Potential of ENPP3 as a Therapeutic Target in ccRCC
July 18th 2025, 6:38pm
Ritesh R. Kotecha, MD, discusses the rationale for targeting ENPP3 in clear cell renal cell carcinoma.
Pembrolizumab/Lenvatinib Combination Produces Durable Responses in Advanced Non–Clear Cell RCC
July 18th 2025, 5:57pm
Findings from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.
Dr Runcie on Treatment Approaches in RCC After Progression on Adjuvant Therapy
July 18th 2025, 3:05pm
Karie Danielle Keera Runcie, MD, discusses treatment challenges after progression on adjuvant therapy and the potential role for zanzalintinib in renal cell carcinoma.
Belzutifan Prolongs Quality-Adjusted Time Without Symptoms or Toxicity in Advanced RCC
July 18th 2025, 2:47pm
Treatment with belzutifan increased the time without progression or toxicity vs everolimus in patients with advanced RCC.
Metastasis-Directed Radiotherapy Yields Durable Disease Control Without Systemic Therapy in Oligometastatic RCC
July 18th 2025, 2:24pm
Metastasis-directed radiotherapy without systemic therapy demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.
Dr Powles on Results from a Q-TWiST Analysis of Belzutifan vs Everolimus in Previously Treated Advanced RCC
July 17th 2025, 11:26pm
Thomas Powles, MD, discusses results from a Q-TWiST analysis of belzutifan vs everolimus in previously treated advanced renal cell carcinoma.
Dr Machaalani on the Potential Role of Circulating KIM-1 as a Biomarker in Metastatic RCC
July 17th 2025, 11:15pm
Marc Machaalani, MD, discusses retrospective findings from a multi-platform analysis evaluating circulating KIM-1 as a biomarker in metastatic RCC.
Investigational Neoantigen Vaccines Target RCC Mutations and Drive Durable T-Cell Activity
July 17th 2025, 8:34pm
David A. Braun, MD, PhD, discusses findings from a study of personalized neoantigen vaccines in patients with high-risk, resectable ccRCC.
Novel CAR T-Cell Therapy Could Pave the Way for Improvements in Advanced ccRCC Management
July 17th 2025, 8:33pm
Research supports the use of novel CAR T-cell therapy targeting CAIX and CD70 for the treatment of patients with advanced ccRCC.
Dr Tarantino on the Role of ADCs in HER2+ Breast Cancer
July 11th 2025, 9:08pm
Paolo Tarantino, MD, details the role of ADCs in HER2-positive breast cancer, along with unmet needs that persist.
Dr McArthur on the Efficacy of Pembrolizumab Plus Neoadjuvant Chemo in TNBC
July 11th 2025, 7:31pm
Heather McArthur, MD, MPH, FASCO, discusses the efficacy of pembrolizumab/chemo and sequencing the regimen in early triple-negative breast cancer.
Dr Azenkot on Dupilumab Plus Cemiplimab in Early-Stage, Resectable NSCLC
July 7th 2025, 9:41pm
Tali Azenkot, MD, discusses the rationale for combining dupilumab with cemiplimab in early-stage, resectable non–small cell lung cancer.